临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 93-14-1

Guaifenesin

中文名称:愈创甘油醚
CAS号:93-14-1
分子式: C10H14O4 分子量: 198.22
产品形式: free base
研发状态: Completed
研发用途: Healthy Subjects
研究机构: Reckitt Benckiser Inc.; Reckitt Benckiser LLC
研发日期: June 2 2013
研发阶段: Phase 1
Guaifenesin is an expectorant used to relieve chest congestion.

CAS: 93107-08-5

Ciprofloxacin hydrochloride

中文名称: 盐酸环丙沙星
CAS号:93107-08-5
分子式: C17H19ClFN3O3 分子量: 367.80
产品形式: Hydrochloride
研发状态: Not yet recruiting
研发用途: Patients withInfections Caused by S.Aureus Like Skin Infections Chest Infections Surgical Site Infections and Urinary Tract Infections
研究机构: Sohag University
研发日期: May-23
研发阶段: Not Applicable
Ciprofloxacin (CPX, Cetraxal, Ciloxan, Cipro, Bay-09867) hydrochloride, a fluorinated quinolone, is a β-diketone antibiotic with a broad spectrum antibacterial activity. Ciprofloxacin is an inhibitor of bacterial DNA gyrase (a subclass of Type II topoisomerases).

CAS: 929095-18-1

GSK461364

CAS号:929095-18-1
分子式: C27H28F3N5O2S 分子量: 543.60
产品形式: free base
研发状态: Completed
研发用途: Lymphoma Non-Hodgkin
研究机构: GlaxoSmithKline
研发日期: August 16 2007
研发阶段: Phase 1
GSK461364 (GSK461364A) inhibits purified Plk1 with Ki of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3.

CAS: 929016-96-6

Pracinostat (SB939)

中文名称:(2E)-3-[2-丁基-1-[2-(二乙基氨基)乙基]-1H-苯并咪唑-5-基]-N-羟基丙烯酰胺
CAS号:929016-96-6
分子式: C20H30N4O2 分子量: 358.48
产品形式: free base
研发状态: Completed
研发用途: Healthy Volunteers; Non-smokers
研究机构: Helsinn Healthcare SA
研发日期: May-14
研发阶段: Phase 1
Pracinostat (SB939) is a potent pan-HDAC inhibitor with IC50 of 40-140 nM with exception for HDAC6. It has no activity against the class III isoenzyme SIRT I. Pracinostat (SB939) induces apoptosis in tumor cells. Phase 2.

CAS: 928659-70-5

Eliglustat hemitartrate

中文名称:依利格鲁司特酒石酸盐
CAS号:928659-70-5
分子式: C50H78N4O14 分子量: 959.17
产品形式: Hemitartrate
研发状态: Completed
研发用途: Gaucher Disease Type 1
研究机构: Genzyme a Sanofi Company; Sanofi
研发日期: Nov-09
研发阶段: Phase 3
Eliglustat hemitartrate (Genz-112638, Eliglustat tartrate) is a potent, specific and orally active inhibitor of glucosylceramide synthase with IC50 of 24 nM.

CAS: 928659-17-0

Triazavirin

CAS号:928659-17-0
分子式: C5H7N6NaO5S 分子量: 286.20
产品形式: free base
研发状态: Terminated
研发用途: Covid19
研究机构: Wits Health Consortium (Pty) Ltd; PharmaCentrix (Pty) Ltd; Perinatal HIV Research Unit of the University of the Witswatersrand
研发日期: September 8 2020
研发阶段: Phase 2 : Phase 3
Triazavirin (TZV, Riamilovir) is a novel antiviral drug, a nucleoside analogue of nucleic acid that inhibits the synthesis of viral RNA and DNA and replication of genomic fragments. Triazavirin is active against influenza and a number of other viruses. Triazavirin is an effective protective agent on the transmission stage of influenza.